APO RESEARCH · REPORT
Duchenne Muscular Dystrophy (DMD) Therapeutics
Duchenne muscular dystrophy, sometimes shortened to DMD or just Duchenne, is a rare genetic disease. It predominantly affects males, but, in rare cases, can also affect females. Duchenne causes the muscles in the body to become weak and damaged over time and is eventually fatal. The genetic change that causes Duchenne—a mutation in the DMD gene—happens before birth and can be inherited, or new mutations in the gene can occur spontaneously. Muscle weakness becomes increasingly noticeable between the ages of 3 and 5, and most patients use a wheelchair by the time they are 12. During adolescence, heart and breathing muscles weaken, leading to serious, life-threatening complications.
Product & engineering
Understand the product.
Duchenne muscular dystrophy, sometimes shortened to DMD or just Duchenne, is a rare genetic disease. It predominantly affects males, but, in rare cases, can also affect females. Duchenne causes the muscles in the body to become weak and damaged over time and is eventually fatal. The genetic change that causes Duchenne—a mutation in the DMD gene—happens before birth and can be inherited, or new mutations in the gene can occur spontaneously. Muscle weakness becomes increasingly noticeable between the ages of 3 and 5, and most patients use a wheelchair by the time they are 12. During adolescence, heart and breathing muscles weaken, leading to serious, life-threatening complications.
Selected research
Industry Research
Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Research Report 2026
Market perspective
Duchenne muscular dystrophy, sometimes shortened to DMD or just Duchenne, is a rare genetic disease. It predominantly affects males, but, in rare cases, can also affect females. Duchenne causes the muscles in the body to become weak and damaged over time and is eventually fatal. The genetic change that causes Duchenne—a mutation in the DMD gene—happens before birth and can be inherited, or new mutations in the gene can occur spontaneously. Muscle weakness becomes increasingly noticeable between the ages of 3 and 5, and most patients use a wheelchair by the time they are 12. During adolescence, heart and breathing muscles weaken, leading to serious, life-threatening complications.
By region, North America has the highest market share, reaching 70.66% in 2019.
Sarepta Therapeutics and PTC Therapeutics hold amlost the whole market.
Read the full market overview
Report Scope
This report quantifies the global Duchenne Muscular Dystrophy (DMD) Therapeutics market in terms of revenue (US$ million) and, where applicable, service volume (), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Duchenne Muscular Dystrophy (DMD) Therapeutics.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Duchenne Muscular Dystrophy (DMD) Therapeutics Market by Company
Sarepta Therapeutics
PTC Therapeutics
Pfizer
Bristol-Myers Squibb
Italfarmaco
Santhera Pharmaceuticals
Duchenne Muscular Dystrophy (DMD) Therapeutics Segment by Type
Exondys
Emflaza
Translarna
Duchenne Muscular Dystrophy (DMD) Therapeutics Segment by Application
Hospitals
Clinics
Home Care
Duchenne Muscular Dystrophy (DMD) Therapeutics Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Duchenne Muscular Dystrophy (DMD) Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Duchenne Muscular Dystrophy (DMD) Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Duchenne Muscular Dystrophy (DMD) Therapeutics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Duchenne Muscular Dystrophy (DMD) Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Exondys
- Emflaza
- Translarna
Applications
- Hospitals
- Clinics
- Home Care
Companies covered
- Sarepta Therapeutics
- PTC Therapeutics
- Pfizer
- Bristol-Myers Squibb
- Italfarmaco
- Santhera Pharmaceuticals
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Duchenne Muscular Dystrophy (DMD) Therapeutics by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Exondys
- 2.2.3 Emflaza
- 2.2.4 Translarna
- 2.3 Duchenne Muscular Dystrophy (DMD) Therapeutics by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hospitals
- 2.3.3 Clinics
- 2.3.4 Home Care
- 2.4 Assumptions and Limitations
3 Duchenne Muscular Dystrophy (DMD) Therapeutics Breakdown Data by Type
- 3.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Historic Market Size by Type (2021-2026)
- 3.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Forecasted Market Size by Type (2027-2032)
4 Duchenne Muscular Dystrophy (DMD) Therapeutics Breakdown Data by Application
- 4.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Historic Market Size by Application (2021-2026)
- 4.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Perspective (2021-2032)
- 5.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Growth Trends by Region
- 5.2.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Historic Market Size by Region (2021-2026)
- 5.2.3 Duchenne Muscular Dystrophy (DMD) Therapeutics Forecasted Market Size by Region (2027-2032)
- 5.3 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Dynamics
- 5.3.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Trends
- 5.3.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Drivers
- 5.3.3 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Challenges
- 5.3.4 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Duchenne Muscular Dystrophy (DMD) Therapeutics Players by Revenue
- 6.1.1 Global Top Duchenne Muscular Dystrophy (DMD) Therapeutics Players by Revenue (2021-2026)
- 6.1.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Players (2021-2026)
- 6.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Duchenne Muscular Dystrophy (DMD) Therapeutics Head Office and Area Served
- 6.4 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Players, Product Type & Application
- 6.5 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Manufacturers Established Date
- 6.6 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (2021-2032)
- 7.2 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2021-2026)
- 7.4 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (2021-2032)
- 8.2 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2021-2026)
- 8.4 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (2021-2032)
- 9.2 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (2021-2032)
- 10.2 South America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2021-2026)
- 10.4 South America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (2021-2032)
- 11.2 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Sarepta Therapeutics
- 12.1.1 Sarepta Therapeutics Company Information
- 12.1.2 Sarepta Therapeutics Business Overview
- 12.1.3 Sarepta Therapeutics Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2021-2026)
- 12.1.4 Sarepta Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Product Portfolio
- 12.1.5 Sarepta Therapeutics Recent Developments
- 12.2 PTC Therapeutics
- 12.2.1 PTC Therapeutics Company Information
- 12.2.2 PTC Therapeutics Business Overview
- 12.2.3 PTC Therapeutics Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2021-2026)
- 12.2.4 PTC Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Product Portfolio
- 12.2.5 PTC Therapeutics Recent Developments
- 12.3 Pfizer
- 12.3.1 Pfizer Company Information
- 12.3.2 Pfizer Business Overview
- 12.3.3 Pfizer Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2021-2026)
- 12.3.4 Pfizer Duchenne Muscular Dystrophy (DMD) Therapeutics Product Portfolio
- 12.3.5 Pfizer Recent Developments
- 12.4 Bristol-Myers Squibb
- 12.4.1 Bristol-Myers Squibb Company Information
- 12.4.2 Bristol-Myers Squibb Business Overview
- 12.4.3 Bristol-Myers Squibb Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2021-2026)
- 12.4.4 Bristol-Myers Squibb Duchenne Muscular Dystrophy (DMD) Therapeutics Product Portfolio
- 12.4.5 Bristol-Myers Squibb Recent Developments
- 12.5 Italfarmaco
- 12.5.1 Italfarmaco Company Information
- 12.5.2 Italfarmaco Business Overview
- 12.5.3 Italfarmaco Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2021-2026)
- 12.5.4 Italfarmaco Duchenne Muscular Dystrophy (DMD) Therapeutics Product Portfolio
- 12.5.5 Italfarmaco Recent Developments
- 12.6 Santhera Pharmaceuticals
- 12.6.1 Santhera Pharmaceuticals Company Information
- 12.6.2 Santhera Pharmaceuticals Business Overview
- 12.6.3 Santhera Pharmaceuticals Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2021-2026)
- 12.6.4 Santhera Pharmaceuticals Duchenne Muscular Dystrophy (DMD) Therapeutics Product Portfolio
- 12.6.5 Santhera Pharmaceuticals Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst